de-escalation

At the 2026 EBCC, Jelle Wesseling MD PhD discusses the LORD-trial, which found active surveillance for low-risk, estrogen-receptor-positive, HER2-negative, grade 1–2 DCIS is as effective as standard therapy. The trial's reassuring findings led to early cessation of randomization, supporting de-escal

HEIDELBERG, Germany—André Pfob, Clinical Research Assistant from the University Breast Unit at Heidelberg University Hospital, Germany tells the Audio Journal of Oncology’s correspondent Peter